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INTRODUCTION
Phenylketonuria (PKU; MIM 261600) is an autosomal
recessive metabolic disorder caused by a deficiency of pheny-
lalanine hydroxylase (PAH; EC 1.14.16.1) (1, 2). PAH (L-
phenylalanine-4-monooxygenase; EC 1.14.16.1), expressed
predominantly in liver, catalyzes the conversion of the essential
amino acid phenylalanine into tyrosine using tetrahydro-
biopterin (BH4) as a cofactor (3). The dysfunction of this
enzyme results in the accumulation of phenylalanine and its
abnormal derivatives in the blood and other tissues. Untreat-
ed PKU patients exhibit severe mental retardation, cogni-
tive problems, growth failure, and other symptoms such as
hypopigmentation due to a reduction of melanin synthesis
(4, 5). In addition, increased concentration of blood pheny-
lalanine caused by noncompliance to dietary control during
pregnancy has an effect on offspring, leading to birth defects,
the so-called maternal PKU syndrome (6).
To ameliorate PKU-related symptoms, a strict lifelong
dietary restriction of phenylalanine is recommended (7). Gene
transfer technology has been used to deliver recombinant
PAH gene into somatic cells and restore functional protein
(8-11), which can replace the usual dietary treatment. We
have previously demonstrated that recombinant adeno-associ-
ated virus serotype 2 (rAAV-2)-mediated delivery of a human
PAH transgene efficiently induces biochemical and pheno-
typic reversal in an animal PKU model (Pahenu2 mouse), which
resembles the metabolic and biochemical abnormality of
human PKU (12). However, route-independent and long-
term therapeutic effects in females were not achieved in our
earlier study. Recently, other studies demonstrated the com-
plete correction of hyperphenylalaninemia in both males and
females by the rAAV 2/8 vector (13, 14). AAV serotype 8 is
an attractive candidate for liver-targeted gene therapy (15,
16). However, their observations were confined to the cor-
rection in the adult PKU mouse. The clinical use of gene
therapy should completely overcome any possible complica-
tions such as maternal PKU syndrome, so that female PKU
mice reproduce health offspring without birth defects or
growth abnormalities. Here, we report pseudotyped rAAV2/
8-mediated gene therapy that rescues from the effect of mater-
nal PKU to provide long-term and sex-independent thera-
peutic correction of PKU mice.
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Protective Effect of Recombinant Adeno-Associated Virus 2/8-Mediated
Gene Therapy from the Maternal Hyperphenylalaninemia in Offsprings
of a Mouse Model of Phenylketonuria 
Phenylketonuria (PKU) is an autosomal recessively inherited metabolic disorder
caused by a deficiency of phenylalanine hydroxylase (PAH). The accumulation of
phenylalanine leads to severe mental and psychomotor retardation, and the fetus
of an uncontrolled pregnant female patient presents with maternal PKU syndrome.
We have reported previously on the cognitive outcome of biochemical and pheno-
typic reversal of PKU in a mouse model, Pah
enu2, by the AAV serotype 2-mediated
gene delivery of a human PAH transgene. However, the therapeutic efficacy had
been limited to only male PKU mice. In this study, we generated a pseudotyped
recombinant AAV2/8-hPAH vector and infused it into female PKU mice through the
hepatic portal vein or tail vein. Two weeks after injection, complete fur color change
to black was observed in female PKU, as in males. The PAH activity in the liver
increased to 65-70% of the wild-type activity in female PKU mice and to 90% in
male PKU mice. Plasma phenylalanine concentration in female PKU mice decreased
to the normal value. In addition, the offsprings of the treated female PKU mice can
rescue from the harmful effect of maternal hyperphenylalaninemia. These results
indicate that recombinant AAV2/8-mediated gene therapy is a potential therapeu-
tic strategy for PKU.
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Recombinant AAV construction and production
The AAV-2-based human PAH expression vector plasmid,
pAAV2-EF-hPAH-WPRE, was created as described previ-
ously (12). The pAAV2-EF-hPAH-WPRE is a full-length
human PAH cDNA, phPAH247 (ATCC, Manassas, VA,
U.S.A.)-containing vector harboring the human elongation
factor 1-αpromoter (EF), woodchuck hepatitis virus post-
transcriptional element (WPRE), and bovine growth hor-
mone poly (A) signal. The rep2/cap2 plasmid or rep2/cap8
plasmid (p5E18-VD2/8, kindly provided by James M. Wil-
son) (15) was used to package the expression vector. The
rAAV2/2-hPAH and rAAV2/8-hPAH vectors were pro-
duced by the triple plasmid transfection method, purified
by cesium chloride (Sigma-Aldrich, St. Louis, MO, U.S.A.)
density gradient ultracentrifugation (17). The rAAV genom-
ic titer was determined by real-time quantitative PCR using
the ABI7700 (PerkinElmer/Applied Biosystems, Foster City,
CA, U.S.A.), in which the signal from aliquots of the test
material is compared with a standard signal generated using
the linearized pAAV2-EF-hPAH-WPRE plasmid.
Cell culture and animal experiments
The human embryonic kidney cell line, 293T, was propa-
gated in Dulbecco modified Eagle medium supplemented
with heat-inactivated 10% fetal bovine serum and antibi-
otics. The animal protocol was approved by the animal experi-
ment review committee of the Ewha Medical Research Insti-
tute, Ewha Womans University, Korea. A pair of PAH-defi-
cient mice, Pahenu2, were purchased from the Jackson Labo-
ratory (Bar Harbor, ME, U.S.A.), maintained, and bred to
obtain sufficient numbers of Pahenu2 homozygotic mice for
this study (18). Mice had unlimited access to water and a
diet containing 18.0% protein without phenylalanine restric-
tion (Rat & Mouse 18%, PMI Nutrition International, Brent-
wood, MO, U.S.A.) throughout the entire experimental
period. Five- to six-week-old mice were anesthetized with
ketamine-xylazine and infused with 2×1012 viral particles
of rAAV2/2-hPAH or rAAV2/8-hPAH through the hepatic
portal vein. For tail vein injection, 3×1012 viral particles of
rAAV2/8-hPAH was infused. At least three Pahenu2 homozy-
gote mice were grouped and treated for each experiment.
Plasma phenylalanine assay and PAH enzyme assay
Plasma phenylalanine concentration and PAH enzyme activ-
ity in the liver were measured using our previous method
(12). Quantitative analysis of plasma phenylalanine and tyro-
sine concentrations was carried out using high performance
liquid chromatography (Biochrom20, Pharmacia, Cambridge,
England). The PAH enzyme activity was assayed by thin
layer chromatography to measure the production of [14C]tyro-
sine from [14C]phenylalanine. The radioactivity of [14C]pheny-
lalanine and converted [14C]tyrosine was quantified using the
ImageQuant (Amersham, Buckinghamshire, U.K.), after
visualization with a PhosphoImager system (Fuji, Tokyo,
Japan).
The effect of gene therapy on maternal PKU syndrome
Three five- to six-week-old female homozygous Pahenu2
mice were injected with 3×1012 viral particles of rAAV2/
8-hPAH once through the tail vein. After two weeks, each
female mouse was mated with a heterozygous male mouse.
Control wild type and untreated female homozygous mice
were also mated with heterozygous male mice. Females were
checked daily for evidence of a vaginal plug, and on day 18.5
gestation (18.5 dpc), the pregnant female mice were sacri-
ficed and the abdominal cavity was opened. The abortion
rate, crown-rump length, and fetal weight were determined
as described previously (19-21). Crown-rump length was
measured with vernier calipers after removing each fetus from
their gestational sacs (20). To calculate the abortion rate, the
fetuses were individually dissected from the uterine lining
after the gestational sacs were counted. The abortion (resorp-
tion) sites could be identified by their small size accompa-
nied by a necrotic, hemorrhagic appearance, compared with
normal fetuses and placentas. The percentage abortion rate
was calculated as the ratio of resorption sites to total implan-
tation sites (resorption plus normal implantation sites) as
described previously (21). Polymerase chain reaction ampli-
fication with viral-specific primers was used to identify the
transmission of viral particles to placentae and fetuses. The
forward primer for the human elongation factor 1-αpro-
moter was 5′ -CGTCCAGGCACCTCGATTAGT-3′ , and
the reverse primers were 5′ -CAGAGAGTTTCCTGCCCA-
AG-3′ for rAAV2/8-hPAH and 5′ -GTAGGTCAGGGT-
GGTCACGA-3′ for rAAV2/8-eGFP.
Statistical analysis
The statistical significance levels of differences between
groups were determined using Student’s t-test. The data were
presented as mean±SD.
RESULTS
PAH activities and plasma phenylalanine concentration
in PKU mice
PAH activity in livers of the rAAV-hPAH-treated PKU
mice six weeks after treatment recovered to 58.43±5.73%
and 89.25±8.79% of the wild-type activity in female and
male PKU mice, respectively (Fig. 1A). Basal plasma pheny-
878 S.-C. Jung, J.-W. Park, H.-J. Oh, et al.lalanine concentration in untreated seven- to eight-month-
old female mice was 2,891±336.2 μ M, which was higher
than in untreated male mice (1,800.6±233.7 μ M). Plasma
phenylalanine concentration in female PKU mice infused
with high titer rAAV2/8-hPAH vectors (2×1012 viral par-
ticles via the portal vein) decreased markedly to 110±34.5
μ M at two weeks and showed continued significant pheny-
lalanine clearance for six month after rAAV2/8-hPAH infu-
sion (Fig. 1B). The plasma phenylalanine concentration in
female PKU mice infused 3×1012 viral particles via the tail
vein also decreased to the values of wild type mice. Howev-
er, there was no significant reduction of plasma phenylala-
nine concentration in rAAV2/2-hPAH infused female PKU
mice. Plasma phenylalanine level at 6 months after rAAV2/
2-hPAH treatment in female Pahenu2 was not measured since
PAH enzyme activity peaks at 5 weeks after rAAV2/2-hPAH
injection (12). 
The fur color changed from grayish to black in the treat-
ed female PKU mice from one week after delivery of rAAV2/
8-hPAH, similar to the pattern observed in treated male PKU
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Fig. 1. (A) PAH enzyme activity in the livers of Pah
enu2 mice six weeks after rAAV-hPAH administration. Enzymatic activity is represented
as a percentage of that found in wild-type mice. The dotted bar represents PAH activities in homozygous Pah
enu2 mice; the black bars,
rAAV2/8-hPAH-injected homozygous female mice; the opened bars, rAAV2/8-hPAH-injected homozygous male mice. (B) Plasma pheny-
lalanine concentration in female Pah
enu2 mice after rAAV2/2-hPAH or aAAV2/8-hPAH treatment. The dotted bars represent plasma pheny-
lalanine concentrations in homozygous female Pah
enu2 mice 2 weeks after treatment; the black bars, 6 weeks after treatment; the open bars,
6 months after treatment. The dotted line A represents the recommended maximum value by the National Society for PKU (U.K.); dotted
line B, plasma concentration in wild-type control mice. Values are presented as the mean±SD. 
*, p<0.001 vs. untreated Pah
enu2 mice (n=3 for each experiment). 
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Fig. 2. Fur color change to black in rAAV2/8-hPAH-treated Pah
enu2 mice. (A) Female Pah
enu2 mice infused with 2×10
12 viral particles through
the portal vein displayed pigmentation six weeks after injection. (B) Pregnant female Pah
enu2 mice administered with 3×10
12 viral particles
through the tail vein exhibited the fur color change four weeks after injection.
A B Untreated Treated Untreated Treatedmice (Fig. 2A). Sustained fur color changes were observed
over the entire six-month experimental period.
Effect of rAAV2/8-hPAH treatment on pregnant PKU
mice
At 18.5 dpc, plasma phenylalanine concentration was
106.3±19.3 μ M in rAAV2/8-hPAH-treated pregnant PKU
mice and 1,199±63.6 μ M in untreated pregnant PKU mice.
The fur color change also occurred in pregnant female PKU
mice treated with rAAV2/8-hPAH (Fig. 2B). The crown-
rump length and body weight of fetuses from treated PKU
mice were recovered to the wild-type values (Fig. 3A, B).
The mean crown-rump length of fetuses from untreated preg-
nant PKU mother was 1.746±0.203 cm. The mean crown-
rump length of fetuses from rAAV2/8-hPAH treated moth-
er was 2.081±0.269 cm, which is recovered to the value
from wild-type mother, 2.070±0.220 cm. The mean weight
of fetuses from untreated and wild-type mother was 774±
144 mg and 916±67 mg respectively. The mean weight of
fetuses from rAAV2/8-hPAH treated mother was 1,040±
258 mg, that is also recovered to wild-type value. The spon-
taneous abortion rate of homozygous PKU female mice was
30.95±14.27%. The spontaneous abortion rate of treated
PKU mice was 4.55±5.89%, that was also normalized to
the wild-type level, 2.27±4.55% (Fig. 3C). The rAAV-
hPAH genome was not detected in the placentae and fetus-
es of treated PKU mice (data not shown). The genotype of
fetuses did not affect the development parameters, such as
crown-rump length and body weight, of fetuses (Fig. 4). 
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Fig. 3. Analysis of offspring of homozygous PKU female mice. Mean values of crown-rump length (A), weight (B), and spontaneous abor-
tion rates (C) of the fetuses by maternal status. The dotted bars represent offspring of wild type mothers; the black bars, offspring of untreat-
ed homozygous mothers; the opened bars, offspring of rAAV2/8-hPAH-injected homozygous mothers. 
*p<0.001 vs. wild type and untreated mothers, treated and untreated mothers (n=38 for fetuses from 4 wild type mothers, n=29 for fetus-
es from 5 untreated mothers, and n=21 for fetuses from 3 treated mothers).
Fig. 4. (A) Pregnant female Pah
enu2 mice administered
with 3×10
12 viral particles through the tail vein exhibit-
ed the fur color change on day 18.5 gestation. Geno-
typing of fetuses from treated mother was confirmed
by sequencing (n=10). (B) Pregnant female Pah
enu2
mice on day 18.5 gestation and fetuses from untreated
mother. Sequencing was performed for genotyping of
fetuses (n=2). 
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Gene therapy for patients with PKU would be a useful
therapeutic candidate to replace dietary restriction. The recom-
binant AAV vector is the most attractive candidate for ther-
apeutic gene delivery because of its long-term expression
and minimal antigenicity. Gene therapy using recombinant
AAV vectors containing the PAH transgene has been reported
several times (11-14). Earlier recombinant AAV-2 based gene
therapy showed remarkable biochemical and phenotypic cor-
rections in treated PKU mice, including our previous study
(12). However, the therapeutic efficiency was limited to male
PKU mice, and rAAV 2-based gene therapy did not show
efficient therapeutic outcome in female PKU mice. This sex-
ual dimorphism probably originated in the characteristics of
the recombinant AAV vector itself and from the characteris-
tics of the pathophysiology of PKU. Davidoff et al. (22) report-
ed that the transduction of murine liver by recombinant AAV
depends on an androgen-dependent pathway and that the
liver transduction efficiency is influenced by the route of
administration of the rAAV vector. Intrahepatic injection of
the rAAV vector is associated with the fastest and strongest
onset of transgene expression (23). More recently, Chen et al.
(24) reported that the underlying mechanism responsible for
the observed sexual dimorphism in PKU mice after AAV
vector-mediated gene therapy is BH4 suppression by estro-
gen, suggesting that the estrogen-suppressed steady-state
levels of BH4 in mouse hepatocytes is limiting.
Several AAV serotypes have been studied to overcome the
low efficiency of liver transduction of rAAV-2-mediated gene
transfer. The recombinant AAV-2 vector pseudotyped with
the AAV-8 capsid greatly improves liver transduction and
increase transgene expression levels (15, 16). The pseudo-
typed AAV2/8 vector has also been used in gene therapy of
PKU and has achieved long-term complete correction of
PKU in a mouse model (13, 14). These were fascinating and
promising studies of PKU treatment. However, their obser-
vations were limited to adult PKU mice. Therefore, we were
interested in investigating whether the therapeutic efficiency
of rAAV2/8-hPAH in a PKU mouse model could be extend-
ed to the offspring of homozygous PKU mice, i.e., whether
rAAV-hPAH treatment could overcome maternal PKU syn-
drome.
We found that portal vein infusion of pseudotyped rAAV2/
8 vector into female PKU mice achieved very strong PAH
expression and complete correction of plasma phenylalanine
concentration, in accordance with other studies (13, 14). The
PAH enzyme activity in the liver of female PKU mice was
more than 65% of wild-type value. Although the PAH activ-
ity in the treated female mice was still lower than in the treat-
ed male mice, this value was sufficient to achieve phenylala-
nine clearance in the female PKU mice. The plasma pheny-
lalanine clearance in the rAAV2/8-hPAH-treated female PKU
mice was almost normal, which had not been achieved by
rAAV2/2-hPAH vector. The observed fur color change accom-
panied the recovery of PAH activity.
Because of excessive blood phenylalanine concentration in
the pregnant PKU homozygous female Pahenu2 mothers, their
offspring have severe problems, such as growth failure, heart
defects, mental retardation, and stillbirth (7, 18, 25). This
suggests that the offspring of PKU mother treated with
rAAV2/8-hPAH gene therapy could be free from the effect
of maternal PKU.
Interestingly, we observed that the offspring of treated
female PKU mice can escape from the complications of mater-
nal hyperphenylalaninemia. The pregnant females were in-
fused once with the rAAV2/8-hPAH vector through the tail
vein two weeks before conception. The offspring of treated
PKU mice showed no growth retardation and the sponta-
neous abortion rate of treated females recovered to the val-
ues of wild-type pregnant mice. No viral vector sequence
was detected in the fetuses, indicating this therapeutic effect
comes from the normalized blood phenylalanine concentra-
tion in pregnant PKU mice. The genotypes of fetuses were
not correlated with the developmental phenotypes of fetus-
es, demonstrating that the genotype of fetus is not a critical
factor in determining the pregnancy outcome in maternal
PKU syndrome. It is noteworthy, considering that maternal
genotype is an important factor predicting the pregnancy
outcome in maternal PKU syndrome when dietary treatment
is discontinued (26). The fur color change also observed in
the pregnant PKU mice corresponded with PAH activity in
the liver of treated PKU mice (12). The PAH activity in the
rAAV2/8-hPAH-treated PKU mice was sufficient to pre-
vent the blood phenylalanine excess in the pregnant PKU
mice, although these mice were in an unfavorable environ-
ment of high estrogen levels during pregnancy. The high
transduction efficiency of the rAAV2/8 vector can complete-
ly overcome the obstacles of the etiology of sexual dimor-
phism (22, 24). This result also indicates that the single tail
vein injection of rAAV2/8-hPAH into female PKU mice can
achieve high transduction efficiency in the liver.
Since the mating of PKU mice was performed at two weeks
after rAAV-hPAH viral injection, the probability of germ-
line transmission is considered extremely low according to
previous reports (27-29). AAV infectious particles were pre-
sent only as long as day four after viral injection in rabbit
and were not detected thereafter (29). No AAV vector sequ-
ences were detected from rabbit semen collected at time from
seven to ninety days following intramuscular injection of 1×
1013 rAAV vector genomes per kg (27). In addition, the viral
genome was not detected in the placentae and fetuses of treat-
ed PKU mice in our study.
Like other studies using rAAV2/8-mediated gene therapy
(13, 14), we observed the complete correction of plasma
phenylalanine concentration in treated male and female PKU
mice. More importantly, the offspring of the treated female
PKU mice were free of the effect of maternal hyperpheny-
AAV2/8 Mediated Gene Therapy for PKU Mouse Model 881lalaninemia. These results demonstrate that pseudotyped
rAAV2/8 vector-mediated gene therapy is a promising ther-
apeutic strategy for the clinical control of PKU and other
inherited metabolic disorders.
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